The verdict
Our read at a glance.
Whether sotatercept is understood as an approved, disease-modifying add-on for pulmonary arterial hypertension that traps activin signals, rather than a muscle-building or general activin-pathway drug, and whether its blood-count effects are kept in view.
- The signal
- In a randomized trial (STELLAR), sotatercept added to standard therapy improved how far PAH patients could walk and other measures; a later trial (ZENITH) showed it reduced serious clinical worsening and death in high-risk patients, pointing to a disease-modifying effect rather than just symptom relief.
- The unknown
- How its long-term benefits and risks play out, where it fits in the PAH treatment sequence, and how to manage its effects on blood counts (it can raise red cells and lower platelets).
- Our read
- A genuine breakthrough, and a lesson in where a hyped pathway actually pays off. The activin/TGF-beta system gets talked about for muscle, but sotatercept's first big win is in pulmonary arterial hypertension, where trapping activins appears to slow the disease, not just ease symptoms. It is an approved, specialist PAH add-on with real benefits and blood-count risks to monitor, not a muscle or longevity drug.
The mechanism
How it works.
Pulmonary arterial hypertension is driven partly by an imbalance in the TGF-beta family of growth signals: too much 'grow and multiply' signaling from activins, and too little of the opposing brake, lets the cells lining the lung's small arteries overgrow and stiffen, narrowing the vessels and straining the right side of the heart. Sotatercept is a fusion protein built from the catching end of an activin receptor stuck to an antibody tail; it floats in the blood and mops up activins and related signals before they reach cells, a 'ligand trap'. With less activin signaling, the abnormal vessel-wall overgrowth eases. This is the same pathway people target for muscle (where blocking myostatin and activin grows muscle), but here the goal and the approved benefit are in the lungs' blood vessels. Because activins also restrain red-blood-cell production, trapping them tends to raise the red-cell count, which is why blood is monitored.
Safety & regulatory boundary
The consequential part.
Because it grew out of a drug class first studied for blood disorders, sotatercept can raise the red-cell count (risking too-thick blood), lower platelets, and cause bleeding (nosebleeds, gum bleeding) and small spider-like blood vessels (telangiectasias), so blood counts are monitored. It is approved specifically as an add-on for pulmonary arterial hypertension, not for muscle-building, anti-aging, or general use, and it is a specialist-prescribed injection given every few weeks.
What's next
What we're watching.
Long-term outcomes and survival data, its position among PAH therapies, real-world hematologic safety, and what its success says about targeting the activin pathway in vascular disease versus muscle.
Context
Why this is discussed.
The activin/TGF-beta pathway is famous in fitness circles as a target for building muscle (think myostatin and follistatin). Sotatercept works on that same pathway, but its breakthrough is somewhere unexpected: it is the first drug to treat pulmonary arterial hypertension by calming the abnormal cell growth that narrows lung blood vessels, rather than just relaxing them.
The evidence base
14 cited references.
Regulatory & labels1
Merck Sharp & Dohme LLC (FDA label) · 2025
Registered trials4
ClinicalTrials.gov · PHASE2 · NOT_YET_RECRUITING · 2026-08-31
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2025-04-16
ClinicalTrials.gov · PHASE3 · TERMINATED · 2022-03-18
ClinicalTrials.gov · PHASE3 · COMPLETED · 2021-12-01
Indexed literature (PubMed)9
Humbert M et al. · N Engl J Med · 2025
Hoeper MM et al. · N Engl J Med · 2023
Johnson S et al. · Am J Respir Crit Care Med · 2023
Humbert M et al. · N Engl J Med · 2021
Preston IR et al. · Eur Respir J · 2025
McLaughlin VV et al. · N Engl J Med · 2025
Humbert M et al. · Eur Respir J · 2023
Hoeper MM · Eur Respir J · 2025
Ershed M et al. · Expert Rev Respir Med · 2025
Keep reading